11/07/2018 /
Discover the latest about what’s happening at CURE and in our community in the November 2018 CURE Update from Chief Scientific Officer, Laura Lubbers!
11/07/2018 /
Resective surgery is a viable option in some patients to treat seizures that are associated with Lennox-Gastaut syndrome, with a high probability of seizure control and better adaptive function.
11/05/2018 /
The disruption of Dnm1 leads to seizure like-activity in zebrafish, suggesting that this is a promising model system.
11/02/2018 /
Virginia Tech is launching a $2.6 million study, funded by CURE, to determine if traumatic brain injuries can cause changes within the brain that lead to epilepsy.
11/02/2018 /
Clinicians developed and validated a model to help determine the risk of epilepsy in children who have one or more paroxysmal events.
11/02/2018 /
The FDA approved SYMPAZAN™ (clobazam) oral film for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older.
11/01/2018 /
Epidiolex, the first cannabis-based medication approved by the US Food and Drug Administration, is now available by prescription in all 50 states.
10/30/2018 /
Discover research findings about the public attitudes and beliefs about epilepsy, as well as how likely people with epilepsy are to encounter stigma due to negative public attitudes.
10/30/2018 /
Outcomes from using surgical SLA targeting of subcentimeter-sized EZs, located by rs-fMRI, guided surgery for intractable epilepsy demonstrate the highest seizure freedom rate without surgical complications and are a significant improvement over prior reports.
